Revealing a Clear Path Towards a New Era in the Management of Psoriasis

Chairperson:

Christopher E.M. Griffiths¹

Speakers:

Kristian Reich,² Kenneth Gordon³

1. University of Manchester, Manchester, UK
2. Dermatologikum Hamburg, Hamburg, Germany 
3. Northwestern University, Evanston, Illinois, USA

Disclosure:

Prof Griffiths has been a paid adviser to and/or in receipt of research grants from Actelion, Abbvie, Pfizer, LEO Pharma, Galderma, Sandoz, Novartis, MSD, Amgen, Eli Lilly, Janssen, and Incyte. Prof Reich has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis including Abbvie, Amgen, Biogen-Idec, Celgene, Centocor, Covagen, Forward Pharma, GSK, Janssen-Cilag, LEO Pharma, Lilly, Medac, MSD, Novartis, Pfizer, Vertex, and Takeda. Prof Gordon has received research support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, and Merck, and has served as a consultant to Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Medac, Novartis, and Pfizer.

Acknowledgements:

Writing assistance was provided by Dr Nicola Ray, Apothecom Scopemedical Ltd.

Support:

The publication of this article was funded by Novartis. The views and opinions expressed are those of the authors and not necessarily those of Novartis.

Citation:

EMJ Dermatol. 2014;2[1]:42-48. 10.33590/emjdermatol/10314134. https://doi.org/10.33590/emjdermatol/10314134.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.